Physician profile
John M Lewis
NPI 1851364814
$60,558.40
in general payments reported to CMS, 2019-2025
15 companies · $4,205 in 2025
The $4,205 reported for 2025 was more than what 88% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $12K · 2021: $9,786 · 2022: $6,517 · 2023: $4,850 · 2024: $4,038 · 2025: $4,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,775 · Food and Beverage: $2,647 · Consulting Fee: $1,575 · Travel and Lodging: $95.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,775.00 |
| Food and Beverage | $2,647.29 |
| Consulting Fee | $1,575.00 |
| Travel and Lodging | $95.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $24,760.72 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $15,440.62 | 2022-2025 | Vyzulta, Miebo, Lotemax Sm |
| Allergan, INC. | $12,587.70 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,898.26 | 2019-2021 | |
| Abbvie INC. | $2,776.57 | 2022-2025 | |
| Alcon Vision LLC | $936.07 | 2019-2025 | Rocklatan, Hydrus Microstent, Simbrinza |
| Novartis Pharmaceuticals Corporation | $323.63 | 2019 | |
| Glaukos Corporation | $275.63 | 2022-2024 | Idose |
| Sight Sciences, INC. | $174.40 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $159.69 | 2019-2021 | |
| Thea Pharma INC. | $61.52 | 2023-2024 | Iyuzeh |
| Medline Industries Lp | $57.71 | 2023 | |
| Horizon Therapeutics Plc | $38.46 | 2022 | |
| Akorn Operating Company LLC | $37.34 | 2021 | |
| Kala Pharmaceuticals, INC. | $30.08 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.